Aparna Parikh, MD
Enriched profileAssociate Professor of Medicine, Harvard Medical School · Harvard Medical School
Aparna Parikh is Associate Professor of Medicine, Harvard Medical School at Harvard Medical School. OpenAlex indexes 597 publications with 8,772 citations (h-index 37); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Aparna Parikh, M.D., is Associate Professor of Medicine, Harvard Medical School. The public record shows 597 publications with 8,772 citations (h-index 37), centered on Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Circular RNAs in diseases. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Genomics and Diagnostics
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 92.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Medical Director
Center for Young Adult Colorectal Cancer at MGH
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
Sponsor: Massachusetts General Hospital
- COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Sponsor: Massachusetts General Hospital
- Predicting Disease Progression and/or Recurrence in Cancer
Sponsor: Massachusetts General Hospital
Industry payments
Updated 18 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20258 payments
- GlaxoSmithKline, LLC.Program year20255 payments
- Boehringer Ingelheim International GmbHProgram year20252 payments
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms100%Creon100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients
Massachusetts General Hospital
FY2026$267,465K08CA273688 - Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients
Massachusetts General Hospital
FY2025$267,465K08CA273688 - Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients
Massachusetts General Hospital
FY2024$271,298K08CA273688
Congress activity
Updated 18 Oct 2026
132 congress contributions (2013–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A phase 1/2 study of revumenib in patients (pts) with advanced colorectal cancer (CRC) and other solid tumors.
ASCO Annual Meeting
ASCO2026Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.
Clinical cancer research
Article2026 - Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.
Cancer discovery
Article2026 - Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer.
Clinical cancer research
Article2026 - Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
The New England journal of medicine
Clinical Trial2026 - Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors.
Cancer research communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyArticle1,698 citations2021
- 02
- 03
- 04NCCN Guidelines Insights: Rectal Cancer, Version 6.2020Article484 citations2020
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
massgeneralbrigham.org/en/doctors/p/aparna-parikh-3007145
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Mentions by others
where others cite or feature them- Other
oncodaily.com/blog/118866
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneralbrigham.org ↗
Editorial & leadership roles
journal and society appointments- Member
NCCN Guidelines Committee for Colorectal Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Member
NCI Colorectal Task Force
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneralbrigham.org ↗ - Editorial Board Member
OncoDaily
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Editorial Board Member
ecancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ecancer.org ↗ - Fellow
American Society of Clinical Oncology (FASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Supporter
ASCO IDEA (International Development and Education) Program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- Director
Young Adult Colorectal Cancer Program at Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Director
Global Cancer Care Program at Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Co-founder and CEO/Chief Scientist
Reversing Early Recurrence
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneralbrigham.org ↗
Media & interviews
press, podcasts and appearances- Podcast interview: 'Oncology Overdrive' Episode 90 hosted by Shikha Jain
MD (April 4, 2024) - Topic: Global GI Oncology
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hlth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Christos Mantzoros, MD
Harvard Medical School
William Sauer, MD
Harvard Medical School
Aleksandar Videnovic, MD
Harvard Medical School
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH